Proceeds from the financing will be used to fund near-term product launches, product development activities and strategic business initiatives.
Jeffrey Yordon, CEO, founder and chairman of the board of Sagent Pharmaceuticals, said: “This additional financing round will allow us to advance additional products to market and to avail ourselves of compelling, recently discovered product acquisition opportunities.”